Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Pharma Intermediate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN104561142A reveals nitrilase biosynthesis for statin intermediates. Offers mild conditions, high yield, and supply chain stability for global pharmaceutical manufacturing.
Patent CN107935802A reveals a mild Suzuki coupling method using arylsulfonyl fluoride. This breakthrough offers significant cost reduction and supply chain reliability for fine chemical manufacturing.
Patent CN114150009A reveals a novel enzymatic route for ephedrine using engineered E. coli and yeast, offering high yield and environmental compliance for pharma supply chains.
Patent CN120865012A reveals high-purity synthesis for diatrizoic acid impurity D, ensuring supply chain reliability and cost reduction in pharmaceutical manufacturing.
Patent CN112175892B reveals a novel co-expression engineering bacterium reducing PLP dependency. Discover cost-effective antibiotic intermediate manufacturing solutions.
Patent CN102911079A details a continuous catalytic distillation method for alkoxyl amine hydrochloride, offering high purity and reduced solvent usage for pharmaceutical intermediates.
Patent CN103014081A details a green enzymatic route for 3-amino-4-(2,4,5-trifluorophenyl)methyl butyrate, offering superior chirality and cost reduction in pharmaceutical intermediate manufacturing.
High-yield imine reductase method for ephedrine production offers supply chain stability and cost efficiency for pharmaceutical intermediates.
Patent CN116926574A reveals a green electrochemical method for spirocyclic indoles, eliminating metal catalysts and oxidants for cost-effective pharmaceutical intermediate manufacturing.
Novel synthesis route for 2-deoxy-D-glucose via glucosamine. Reduces cost and complexity. Ideal for API manufacturing scale-up and high-purity production.
Patent CN105130924A offers high-yield synthesis for Febuxostat intermediate. Achieve 99% purity with reduced costs and scalable pharmaceutical intermediate production processes.
Patent CN107686457A details ferrous salt catalysis for high-purity pharmaceutical intermediates. Discover cost reduction and supply chain advantages.
Patent CN112679570A details a robust synthesis of Tildipirosin from Tylosin phosphate, offering high purity >99% and simplified purification for reliable veterinary drug intermediate supply chains.
Patent CN110951706B details a high-activity R-omega-TA mutant for sitagliptin. Offers high ee value >99%, breaking technical monopolies and ensuring supply chain stability.
Patent CN112724003B reveals a safer, high-yield route for 9-fluorenylformaldehyde using mixed alkoxides, offering significant cost reduction in pharmaceutical intermediate manufacturing.
Patent CN101429192A details a novel chiral titanium catalysis method for high-purity proton pump inhibitor intermediates, offering significant supply chain and cost advantages.
Novel fragment condensation method for Liraglutide improves purity and yield while reducing resin consumption for scalable manufacturing processes.
Patent CN111235123A reveals a novel carbonyl reductase enabling high-substrate loading biocatalysis, offering significant cost reduction and purity advantages for pharmaceutical manufacturing.
Patent CN110577941A reveals mutated amine dehydrogenase for asymmetric reductive amination. Enables cost reduction in pharmaceutical intermediates manufacturing with high optical purity.
Patent CN111100851B discloses high-efficiency TbSADH mutants for synthesizing chiral biaryl alcohols with >99% ee, offering a green alternative to metal catalysis.